Table 2.
Risk factors of oral mucositis.
| Total patients | Lymphoma | Myeloma multiplex | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Univariable analysis | ||||||
| Age at the time of Tx (years) | 0.988 (0.964–1.015) | 0.371 | 0.988 (0.952–1.025) | 0.526 | 1.024 (0.970–1.082) | 0.384 |
| Dg-Tx time interval (months) | 1.004 (0.991–1.016) | 0.542 | 0.999 (0.985–1.013) | 0.897 | 0.999 (0.970–1.029) | 0.950 |
|
Amount of stem cells (106/body mass kg) |
0.967 (0.830–1.127) | 0.668 | 1.021 (0.81–1.285) | 0.863 | 0.908 (0.731–1.127) | 0.382 |
| Viability (%) | 1.022 (0.959–1.090) | 0.503 | 1.016 (0.925–1.116) | 0.744 | 1.062 (0.963–1.172) | 0.226 |
|
Amount of viable cells (106/body mass kg) |
0.965 (0.813–1.146) | 0.688 | 1.025 (0.787–1.335) | 0.853 | 0.909 (0.715–1.157) | 0.439 |
|
MNC (108/body mass kg) |
1.033 (0.930–1.147) | 0.547 | 1.034 (0.89–1.2) | 0.664 | 0.989 (0.833–1.166) | 0.868 |
| ANC < 0.5 G/L (days) | 1.461 (1.225–1.744) | < 0.001 | 1.584 (1.134–2.214) | 0.007 | 1.39 (1.09–1.773) | 0.008 |
| THR < 20 G/L (days) | 1.178 (1.078–1.288) | < 0.001 | 1.279 (1.043–1.57) | 0.018 | 1.128 (1.009–1.262) | 0.034 |
| LDH (U/L) | 1.004 (1–1.009) | 0.067 | 1.005 (0.998–1.012) | 0.168 | 1.002 (0.996–1.008) | 0.526 |
| Female versus male | 1.969 (1.052–3.687) | 0.034 | 5.294 (1.418–19.762) | 0.013 | 1.462 (0.67–3.194) | 0.340 |
| Advanced stage at the time of the diagnosis | 1.447 (0.545–3.842) | 0.458 | 0.571 (0.054–6.079) | 0.643 | 1.120 (0.278–4.508) | 0.873 |
| Advanced stage before transplantation | 1.143 (0.594–2.198) | 0.689 | 0.553 (0.19–1.606) | 0.276 | 1.828 (0.778–4.297) | 0.166 |
| Infection | 1.901 (0.894–1.041) | 0.095 | 1.122 (0.396–3.178) | 0.828 | 2.608 (0.795–8.554) | 0.114 |
| HL-NHL | 1.455 (0.468–4.524) | 0.518 | 1.455 (0.468–4.524) | 0.518 | – | – |
| MM-NHL | 0.563 (0.282–1.124) | 0.103 | – | – | – | – |
| L-MM | 1.969 (1.052–3.687) | 0.034 | – | – | – | – |
| Stage of missing of B symptoms | – | – | 7.000 (1.085–45.16) | 0.041 | ||
| IgA versus IgG | – | – | – | – | 2.766 (0.984–7.773) | 0.054 |
| Kappa versus lambda | – | – | – | – | 0.644 (0.291–1.425) | 0.277 |
| Dosis of melphalan (≥ 200 mg/m2) | – | – | – | – | 1.046 (0.301–3.629) | 0.944 |
| MM pretreatment | – | – | – | – | 1.559 (0.464–5.231) | 0.472 |
| Multivariable analysis | ||||||
| ANC ˂ 0.5 G/L (days) | 1.492 (1.228–1.813) | < 0.001 | 1.476 (1.061–2.052) | 0.021 | 1.39 (1.09–1.773) | 0.008 |
| Gender | 2.301 (1.124–4.714) | 0.023 | 4.190 (1.081–16.240) | 0.038 | ||
p < 0.05 was considered significant. p values with bold are significant, while with italic, are non-significant, but close to it.
Statistical analysis: binary logistic regression was used.
ANC absolute neutrophil count, Dg diagnosis, HL Hodgkin lymphoma, IgA immunoglobulin A, IgG immunoglobulin G, L lymphoma, LDH lactate-dehydrogenase, MM Multiple myeloma, MNC mononuclear cells, n numero, NHL Non-Hodgkin’s lymphoma, OM oral mucositis, THR thrombocyte count, Tx transplantation.